Pediatric Study Delays Could Draw Civil Penalties Under Proposal For PREA, BPCA Reauthorization

Civil penalties would be more flexible than FDA’s current authority to label a drug misbranded if sponsors fail to conduct pediatric studies, Commissioner Hamburg argues as the House Energy and Commerce Committee’s Health Subcommittee opens hearings on reauthorizing prescription drug user fees.